Amended and Restated Offer Letter, dated October 22, 2020, between MarkForged, Inc. and Shai Terem

EX-10.30 17 tm2110830d2_ex10-30.htm EXHIBIT 10.30

 

Exhibit 10.30

 

 

 

October 21, 2020

 

Shai Terem (via e-mail)

 

Re:Amended and Restated Offer Letter

 

Dear Shai:

 

The investor directors and the independent directors of the Board of Directors (the “Board”) of Markforged, Inc. (“Markforged” or the “Company”) are pleased to present you with this Amended and Restated Offer Letter, which will govern your continuing at-will employment with the Company effective as of October 22, 2020 (the “Effective Date”) subject to the terms and conditions below. The Board values your significant contributions to the Company’s growth and is excited to continue working with you in this new role.

 

1.             Position: As of the Effective Date, you will serve as the President and Chief Executive Officer of the Company (“CEO”). This is a full-time, exempt position that reports to the Board. You are required to work cooperatively with the Company’s executives, including the Chairman. You will also serve on the Board, subject to applicable Board governance documents, for so long as you remain the CEO, provided that you will be deemed to have resigned from the Board and from any related positions upon ceasing to serve as CEO for any reason. While you render services to the Company, you agree that you will not engage in any other employment, consulting or other business activity without the written consent of the Board.

 

2.             Cash Compensation: Your base salary will be paid at the rate of $500,000 per year, which may be subject to increases from time to time in the discretion of the Company. Your base salary in effect at any given time is referred to herein as “Base Salary.” The Base Salary shall be payable in a manner that is consistent with the Company’s usual payroll practices for executive officers.

 

With respect to your 2020 annual bonus, the Board has determined that you have met 100% of the goals related to the period between January 1 and June 30, 2020, and, although no specific KPI’s were agreed upon by you and the Board for the period between July 1 and December 31, 2020, the Board will assume that you have achieved 100% of such goals. Your 2020 bonus will be paid no later than March 15, 2021. Your annual bonus eligibility will continue to be $200,000 per year, subject to the Company’s determination as provided below. The target annual bonus in effect at any given time is referred to herein as the “Target Bonus.” The actual amount of the annual bonus, if any, shall be determined in the sole discretion of the Board or the Compensation Committee of the Board, subject to the terms of any applicable incentive compensation plan that may be in effect from time to time. Except as provided in Section 7(b) below or as may be provided by the Board or the Compensation Committee, you must be employed by the Company on the date the bonus is paid in order to earn or receive any bonus. The Company may from time to time adopt one or more bonus plans governing the payment of the bonus.

 

 

 

 

In addition, you will be eligible for a special milestone bonus of up to $100,000 per calendar year (the “Special Milestone Bonuses”), to be paid on a quarterly basis (up to $25,000 per quarter), based on the Board’s assessment of your achievement of measurable KPIs s to be established by the Board after consultation with you. Any quarterly payment of a Special Milestone Bonus will be paid to you within 30 days following the Board’s determination with respect to achievement of the applicable milestones and the amount of the quarterly payment (if any) to be awarded. You must be employed on the date of payment to earn any portion of the Special Milestone Bonus.

 

3.            True-Up Option: Subject to customary approval by the Board, and as mutually agreed upon consideration for noncompetition provisions set forth in the attached Confidentiality, Assignment, Nonsolicitation and Noncompetition Agreement (the “Nondisclosure and Noncompetition Agreement”), the Company shall grant you a stock option under the Company’s 2013 Stock Incentive Plan (the “Plan”) to purchase 2,961,167 shares of common stock (which, together with all other equity awards previously granted to you, represents 4.25% of the fully-diluted shares outstanding) at a price per share equal to the fair market value established at the time of Board approval (the “ True-Up Option”). 25% of the shares underlying the True-Up Option will vest on the first anniversary of the Effective Date, and the remaining shares will vest in 36 equal monthly installments thereafter over a total vesting period of four years, provided that you remain an employee of the Company on each such vesting date. The True-Up Option will be subject to the terms of the Plan and subject to and contingent upon your execution of a stock option agreement (the “Stock Option Agreement”, together with the Plan and your existing equity awards, the “Equity Documents”). The Stock Option Agreement shall expressly provide that, following the termination of your employment for any reason other than for Cause (as defined below), the shares underlying the Option may be exercised, to the extent then vested, for a period of one year following the date of termination (but no later than the expiration date of the Option). Notwithstanding anything to the contrary in the Equity Documents, if after the consummation of a Change in Control Transaction (as defined below), you are terminated without Cause (as defined below), then 100% of the then unvested shares underlying the Option and your previously granted equity awards shall become vested.

 

4.             Other Benefits: In addition to your compensation set forth above, during your employment, you will be eligible to participate in the employee benefit plans made generally available by the Company from time to time to its employees, subject to plan terms and generally applicable Company policies.

 

5.             Relocation: You acknowledge and agree that you are required to relocate your primary residence from New Jersey to the Boston, MA area at such time as a COVID-19 vaccine becomes reasonably available to you and your family. Your failure to do so will be considered a material breach by you of this letter agreement and, notwithstanding any other term of this letter agreement, the Company may terminate your employment without any further financial liability to you as if you had been terminated for Cause, as defined below. At the time of such relocation:

 

(a)the Board will make reasonable, good faith efforts to help you obtain liquidity of up to $1,000,000 to the extent you have not already achieved such liquidity including, without limitation, upon any acquisition of the Company by a special purpose entity. To the extent that you have received liquidity in an amount less than $1,000,000 at the time of the relocation, the Board will make reasonable, good faith efforts to help you obtain liquidity of the difference between the liquidity you have then achieved and $1,000,000.

 

 

 

 

(b)the Company shall cover the following: (i) reasonable costs of movers to transfer your household belonging to the Boston area; (ii) commission for house sale (assumed to be approximately 6% of $1,000,000); (iii) reasonable hotel costs, if needed, for any gap between permanent housings; (iv) travel costs and accommodations until relocation to Boston. These reimbursements shall be tax grossed up if needed.

 

6.            Travel: Prior to relocating your primary residence to the Boston, MA area, you are required to work regularly from the Company’s Watertown, MA offices. You also will be required to travel from time to time, consistent with the Company’s business needs. International travel on Company business may be on business class; all other business travel shall be on coach.

 

7.             Severance Upon a Qualifying Termination: If you have a Qualifying Termination and you satisfy the Release Requirement, the Company shall pay or otherwise provide the following to you:

 

(a)The Company shall pay you on regular payroll dates for the Severance Period at the rate of your Base Salary on the date of termination (the “Severance Pay”); provided that (i) the Company may commence payments of Severance Pay at any time within 60 days after the date of termination; (ii) if such sixty (60) day period crosses two calendar years, payments of the Severance Pay shall commence in the second calendar year; and (iii) the initial payment of the Severance Pay shall include a catch-up payment for the period between the date of termination and the beginning of the payroll period applicable to the first payroll date. You shall promptly notify the Company if you secure Other Employment and you shall respond fully to any reasonable inquiries by the Company that relate to its rights to cease Severance Pay in the event you commence Other Employment. The Severance Pay will be subject to tax and other withholdings as required by law. Each payment pursuant to this letter agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).

 

(b)If your Qualifying Termination occurs between the end of a calendar year and the date of payouts of bonuses for such calendar year, the Company shall pay you the bonus for such recently completed calendar year. If the Company has determined such bonus level before the Qualifying Termination, the bonus shall be paid in such amount. If the Company has not determined such bonus level before the Qualifying Termination, the Company shall determine such bonus level in good faith and pay such amount upon determination.

 

For the avoidance of doubt, each of the foregoing is subject to your satisfaction of the Release Requirement.

 

 

 

 

8.             Definitions:

 

(a)            “Cause” means any of the following: (i) conduct by you constituting an act of misconduct in connection with the performance of your duties, including, without limitation, misappropriation of funds or property of the Company or any of its subsidiaries or affiliates other than the occasional, customary and de minimis use of Company property for personal purposes; (ii) the commission by you of (A) any felony or (B) a misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) any conduct by you that would reasonably be expected to result in injury or reputational harm to the Company or any of its subsidiaries and affiliates if you were retained in your position; (iv) continued non-performance by you of your duties hereunder (other than by reason of your physical or mental illness, incapacity or disability) which has continued for more than 30 days following written notice of such non-performance from the Board; (v) a breach by you of any of the provisions of the Nondisclosure and Noncompetition Agreement; (vi) a violation by you of the Company’s written employment policies; or (vii) failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Company to cooperate, or the destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation.

 

(b)            “Change in Control Transaction” means (i) the consolidation or merger of the Company into or with any other entity or entities (except a consolidation or merger into a subsidiary or merger in which the Company is the surviving corporation and the holders of the Company’s voting stock outstanding immediately prior to the transaction constitute not less than the holders of a majority of the voting stock of the surviving, successor or parent entity (as applicable) outstanding immediately following the transaction); (ii) the sale, transfer or exclusive license by the Company of all or substantially all of its assets; or (iii) the sale, exchange or transfer by the Company’s stockholders, in a single transaction or series of related transactions, of capital stock representing a majority of the voting power at elections of directors of the Company (other than a transaction or series of transactions in which the Company is the surviving entity and the holders of the Company’s voting stock outstanding immediately prior to such transaction or series of transactions constitute the holders of a majority of the voting stock outstanding immediately following such transaction or series of transactions and specifically excluding a direct issuance of the securities by the Company where the principal business purpose is financing).

 

(c)            “Continuing Obligations” means your obligations pursuant to the Nondisclosure and Noncompetition Agreement and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants.

 

(d)            “Good Reason” means that you have complied with the Good Reason Process (hereinafter defined) following the occurrence of any of the following events: (i) a material diminution in your Base Salary except for across-the-board salary reductions based on the Company’s financial performance similarly affecting all or substantially all senior management employees of the Company; (ii) a material diminution in your responsibilities, authority or duties; (iii) a material change in the principal geographic location at which you are required to provide services to the Company; or (iv) the material breach of this letter agreement by the Company.

 

 

 

 

(e)            “Good Reason Process” means that (i) you reasonably determine in good faith that a “Good Reason” condition has occurred; (ii) you notify the Company in writing of the first occurrence of the Good Reason condition within 30 days of the first occurrence of such condition; (iii) you cooperate in good faith with the Company’s efforts, for a period not less than 30 days following such notice (the “Cure Period”), to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) you terminate your employment within 60 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.

 

(f)             “Other Employment” means employment on a more than half-time basis. For these purposes, any service as an “employee” within the meaning of M.G.L. c. 149, § 148B shall be considered to be “employment.”

 

(g)            “Qualifying Termination” means a termination of your employment by the Company without Cause or a resignation by you for Good Reason.

 

(h)            “Release Requirement” means the requirement that, as a condition of receiving the payments set forth in Section 7 following a Qualifying Termination, (i) you sign a separation agreement in the form proposed by the Company that will include, without limitation, a release of legal claims and a non-disparagement obligation and will provide that all payments of Severance Pay shall immediately cease if you breach any of your Continuing Obligations, and (ii) the separation agreement becomes irrevocable within 60 days after the date of termination or such short period as set forth in the separation agreement.

 

(i)             “Severance Period” means the period immediately following the date of termination of employment until the earlier of (i) twelve months from the date of termination or (ii) the date immediately before you commence Other Employment.

 

9.              Section 409A: Each payment pursuant to the terms of this letter agreement shall be considered a separate payment for purposes of Internal Revenue Code Section 409A (“Section 409A”). A termination of employment shall not be deemed to have occurred for purposes of any provision of this letter agreement providing for the payment of any amount or benefit upon or following a termination of employment unless such termination is also a “separation from service” within the meaning of Section 409A and, for purposes of this letter agreement, references to a “termination,” “termination of employment” or like terms shall mean “separation from service.” Notwithstanding anything to the contrary in this letter agreement, if you are a “specified employee” (within the meaning of Section 409A) on the date of your separation from service, then any payments or benefits that otherwise would be payable pursuant to the terms of this letter agreement within the first six (6) months following your separation from service (the “409A Suspension Period”), shall instead be paid in a lump sum within 14 days after the end of the six (6) month period following your separation from service, or your death, if sooner, but only to the extent that such payments or benefits provide for the “deferral of compensation” within the meaning of Section 409A, after application of the exemptions provided in Sections 1.409A-1(b)(4) and 1.409A-1(b)(9)(ii)-(v) thereof. After the 409A Suspension Period, you will receive any remaining payments and benefits due in accordance with the terms of this letter (as if there had not been any suspension beforehand). The Company will cooperate with you in making any amendments to this letter that you reasonably request to avoid the imposition of taxes or penalties under Section 409A of the Code provided that such changes do not provide you with additional benefits (other than de minimis benefits) under this terms of this letter.

 

 

 

 

10.           Cooperation: During and after your employment, you shall cooperate with the Company including without limitation in connection with (i) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while you were employed by the Company, provided the Board will make reasonable good faith efforts to limit your future involvement in litigation matters to the extent it is able to do so consistent with its fiduciary duties to the Company; and (ii) the investigation, whether internal or external, of any matters about which the Company believes you may have knowledge or information; or (iii) any other matters that the Board reasonably determines you have knowledge or information about based on your employment with the Company.

 

11.           Withholding; Tax Effect: All payments made by the Company to you under this letter agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law. Nothing in this letter agreement shall be construed to require the Company to make any payments to compensate you for any adverse tax effect associated with any payments or benefits or for any deduction or withholding from any payment or benefit.

 

12.           Jurisdiction: You and the Company hereby consent to the jurisdiction of the state and federal courts of the Commonwealth of Massachusetts. Accordingly, with respect to any such court action, you (a) submit to the exclusive personal jurisdiction of such courts; (b) consent to service of process; and (c) waive any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process.

 

 

 

 

13.           Integration: This letter agreement, together with the Equity Documents, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter, including, without limitation the letter agreement dated August 11, 2019 between you and the Company. Notwithstanding the foregoing, by signing below you acknowledge and agree that Nondisclosure and Noncompetition Agreement remains in full force and effect and is incorporated by reference as materials terms of this letter agreement.1

 

14.           Waiver; Amendment: No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this letter agreement, or the waiver by any party of any breach of this letter agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. This letter agreement may be amended or modified only by a written instrument signed by you and by a duly authorized member of the Board of Directors (other than you).

 

15.           Governing Law: This is a Massachusetts contract and shall be construed under and be governed in all respects by the laws of the Commonwealth of Massachusetts, without giving effect to the conflict of laws principles thereof. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be interpreted and applied by the United States Court of Appeals for the First Circuit.

 

16.           Successors and Assigns: Neither you nor the Company may make any assignment of this letter agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this letter agreement without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization or consolidation, into which the Company merges or to whom it transfers all or substantially all of its properties or assets; provided further that if you remain employed or become employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then you shall not be entitled to any payments pursuant to Section 7 of this letter agreement solely as a result of such transaction. This letter agreement shall inure to the benefit of and be binding upon you and the Company, and each of your and the Company’s respective successors, executors, administrators, heirs and permitted assigns. In the event of your death after your termination of employment but prior to the completion by the Company of all payments due to you under this letter agreement, the Company shall continue such payments to your beneficiary designated in writing to the Company prior to your death (or to your estate, if the you fail to make such designation).

 

17.           Counterparts: This letter agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document.

 

 

 

 

 

 

We hope that you will accept this offer to become the CEO and play a critical role in the continued success of Markforged. You may indicate your agreement with these terms and accept this offer by signing and dating the electronic copy of this offer letter. This offer will expire at 5pm EDT on October __, 2020.

 

We look forward to continuing to work with you. Should you have any questions, please to do hesitate to contact me.

 

Sincerely,  
   
/S /Paul Milbury,  
   
Paul Milbury,  
   
Board Representative  

 

Accepted by:  
   
/s/ Shai Terem  
Shai Terem